POST Online Media Lite Edition


Vir Biotechnology appoints Elliott Sigal to board

Christian Fernsby |
San Francisco, Ca., USA - Vir Biotechnology, a clinical-stage immunology company, announced the appointment of Elliott Sigal to its board of directors.

Dr. Sigal formerly served as Executive Vice President, Chief Scientific Officer and President of Bristol-Myers Squibb Company (BMS) Research and Development, where he played an instrumental role in bringing 14 new medicines to patients in need.

Dr. Sigal advises biotechnology companies, as well as the healthcare team of New Enterprises Associates, a leading venture capital firm.

Dr. Sigal is a member of the board of directors of Adaptimmune Therapeutics plc, and Surface Oncology, Inc., and the private company Affinia Therapeutics Inc.

In addition, he is a member of the Scientific Steering Committee for the Sean Parker Institute for Cancer Immunotherapy and the board of the Melanoma Research Alliance.

Dr. Sigal received his medical degree from the University of Chicago in 1981 and trained in internal medicine and pulmonary medicine at the University of California, San Francisco (UCSF).

He served on the faculty of the UCSF Department of Medicine from 1988-1992.